Deal completion sees Plexxikon become part of Daiichi Sankyo
This article was originally published in Scrip
Following US antitrust clearance, Daiichi Sankyo has completed its acquisition of Plexxikon, successfully sealing a $935 million transaction that will see the formerly private US firm continuing to operate as an independent R&D unit of the Japanese major.
You may also be interested in...
The Daiichi Sankyo affiliate successfully argued that Novartis willfully infringed two patents covering its discoveries in the BRAF inhibitor drug class, getting nearly $178m in damages and future royalties.
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
In this week's podcast edition of Five Must-Know Things: will a new oral antiviral be transformative for COVID?; OX40 drugs gain prominence in atopic dermatitis; J&J adds pace to RSV vaccine race; Sarepta leapfrogs Pfizer in DMD gene therapy; and how real-world evidence and randomized trials might go together.